Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Breast Neoplasms 79Carcinoma, Non-Small-Cell Lung 71Prostatic Neoplasms 68Neoplasms 52Multiple Myeloma 46Lung Neoplasms 42Colorectal Neoplasms 37Melanoma 32Lymphoma, Non-Hodgkin 30Pancreatic Neoplasms 29Neoplasm Metastasis 29Lymphoma 28Leukemia, Myeloid, Acute 27Squamous Cell Carcinoma of Head and Neck 26Ovarian Neoplasms 26Carcinoma, Renal Cell 25Precursor Cell Lymphoblastic Leukemia-Lymphoma 22Leukemia, Lymphocytic, Chronic, B-Cell 22Endometrial Neoplasms 22Stomach Neoplasms 20Sarcoma 20Carcinoma, Hepatocellular 20Urinary Bladder Neoplasms 19Glioma 19Uterine Cervical Neoplasms 18Recurrence 18Rectal Neoplasms 18Lymphoma, Mantle-Cell 17Hematologic Neoplasms 17Head and Neck Neoplasms 17

Interventions

Taxes 1Paclitaxel 1Immunoglobulin G 1Disulfides 1Carboplatin 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Brenner Tumor × 30 days × Clear all
NCT01167712 2026-05-29

Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

National Cancer Institute (NCI)

Phase 3 Active not recruiting
692 enrolled 11 charts
Gynecologic

Brenner Tumor, Fallopian Tube Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡